$ZNTL
Zentalis Pharmaceuticals, Inc.

2022 Q2 Form 10-Q Financial Statement

#000172516022000093 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.64M $11.77M $9.754M
YoY Change 89.5% -1.53% -9.01%
% of Gross Profit
Research & Development $43.83M $46.11M $38.44M
YoY Change -2.11% 20.1% 30.21%
% of Gross Profit
Depreciation & Amortization $348.0K $344.0K $209.0K
YoY Change 192.44% 335.44% 596.67%
% of Gross Profit
Operating Expenses $63.46M $57.88M $48.19M
YoY Change 15.11% 14.96% 19.75%
Operating Profit -$63.46M -$57.88M -$48.19M
YoY Change 15.11% 14.96% 19.75%
Interest Expense $424.0K $426.0K $88.00K
YoY Change 268.7% 204.29% -72.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$63.04M -$57.45M -$48.11M
YoY Change 14.58% 14.34% 20.47%
Income Tax $17.00K $33.00K $159.0K
% Of Pretax Income
Net Earnings -$68.36M -$59.08M -$50.06M
YoY Change 25.26% 18.39% 24.21%
Net Earnings / Revenue
Basic Earnings Per Share -$1.34 -$1.31 -$1.11
Diluted Earnings Per Share -$1.337M -$1.31 -$1.11
COMMON SHARES
Basic Shares Outstanding 46.63M shares 45.24M shares 44.98M shares
Diluted Shares Outstanding 51.12M shares 45.24M shares 44.98M shares

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $455.2M $289.4M $339.9M
YoY Change 81.44% -3.02% 0.41%
Cash & Equivalents $55.14M $30.57M $59.71M
Short-Term Investments $400.1M $258.8M $280.2M
Other Short-Term Assets $12.41M $11.91M $10.88M
YoY Change 45.19% 54.71% 75.47%
Inventory
Prepaid Expenses
Receivables $4.000K
Other Receivables $0.00
Total Short-Term Assets $467.6M $301.3M $350.8M
YoY Change 80.24% -1.66% 1.64%
LONG-TERM ASSETS
Property, Plant & Equipment $51.52M $8.480M $8.148M
YoY Change 2188.89% 462.33% 641.4%
Goodwill $3.736M $3.736M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $30.41M $35.70M $37.50M
YoY Change
Other Assets $14.57M $12.79M $9.667M
YoY Change 70.73% 109.69% 124.81%
Total Long-Term Assets $100.2M $104.4M $103.7M
YoY Change 308.89% 374.54% 407.25%
TOTAL ASSETS
Total Short-Term Assets $467.6M $301.3M $350.8M
Total Long-Term Assets $100.2M $104.4M $103.7M
Total Assets $567.9M $405.7M $454.5M
YoY Change 99.98% 23.55% 24.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.04M $13.16M $11.59M
YoY Change 45.55% 57.89% 33.82%
Accrued Expenses $35.90M $30.32M $32.35M
YoY Change 41.88% 23.97% 62.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.64M $43.49M $43.94M
YoY Change 44.85% 32.59% 53.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $45.07M $44.98M $44.46M
YoY Change 15127.03% 10168.95% 3952.78%
Total Long-Term Liabilities $45.07M $44.98M $44.46M
YoY Change 15127.03% 10168.95% 3952.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.64M $43.49M $43.94M
Total Long-Term Liabilities $45.07M $44.98M $44.46M
Total Liabilities $95.37M $90.01M $90.03M
YoY Change 162.33% 152.03% 179.77%
SHAREHOLDERS EQUITY
Retained Earnings -$418.6M -$359.6M
YoY Change 66.96% 79.03%
Common Stock $46.00K $45.00K
YoY Change 12.2% 9.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $472.5M $315.3M $364.0M
YoY Change
Total Liabilities & Shareholders Equity $567.9M $405.7M $454.5M
YoY Change 99.98% 23.55% 24.33%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$68.36M -$59.08M -$50.06M
YoY Change 25.26% 18.39% 24.21%
Depreciation, Depletion And Amortization $348.0K $344.0K $209.0K
YoY Change 192.44% 335.44% 596.67%
Cash From Operating Activities -$43.03M -$50.20M -$37.02M
YoY Change -6.69% 33.97% 35.31%
INVESTING ACTIVITIES
Capital Expenditures -$278.0K $450.0K -$2.191M
YoY Change -65.89% 3.21% 231.97%
Acquisitions
YoY Change
Other Investing Activities -$141.8M $20.25M $45.46M
YoY Change -310.34% 45.76% -606.21%
Cash From Investing Activities -$142.1M $19.80M $43.27M
YoY Change -313.36% 47.09% -548.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 209.5M $1.258M 12.27M
YoY Change -66383.23% -2179.15%
NET CHANGE
Cash From Operating Activities -43.03M -$50.20M -37.02M
Cash From Investing Activities -142.1M $19.80M 43.27M
Cash From Financing Activities 209.5M $1.258M 12.27M
Net Change In Cash 24.33M -$29.14M 18.51M
YoY Change 20.6% 21.37% -149.24%
FREE CASH FLOW
Cash From Operating Activities -$43.03M -$50.20M -$37.02M
Capital Expenditures -$278.0K $450.0K -$2.191M
Free Cash Flow -$42.75M -$50.65M -$34.83M
YoY Change -5.63% 33.61% 30.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001725160
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39263
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Zentalis Pharmaceuticals, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3607803
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1359 Broadway
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1710
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York,
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10018
CY2022Q1 dei City Area Code
CityAreaCode
212
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
433-3791
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock,$0.001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
ZNTL
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46629804 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30572000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59714000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
258797000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
280173000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
350770000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11670000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10640000 USD
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
243000 USD
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
243000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
301282000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8480000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8148000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43644000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
44691000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
10164000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
7040000 USD
CY2022Q1 us-gaap Goodwill
Goodwill
3736000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
3736000 USD
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
35744000 USD
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
37495000 USD
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2627000 USD
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2627000 USD
CY2022Q1 us-gaap Assets
Assets
405677000 USD
CY2021Q4 us-gaap Assets
Assets
454507000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
13163000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11590000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30322000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32354000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43485000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43944000 USD
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1548000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1622000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44978000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44459000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
90011000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
90025000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45583900 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45583900 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45490764 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45490764 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
46000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
45000 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
734997000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
723593000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1109000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-125000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-418636000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359559000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
315298000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363954000 USD
CY2022Q1 us-gaap Minority Interest
MinorityInterest
368000 USD
CY2021Q4 us-gaap Minority Interest
MinorityInterest
528000 USD
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
315666000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
364482000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
405677000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
454507000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46112000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38394000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11767000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11953000 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
57879000 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
50347000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-57879000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-50347000 USD
CY2022Q1 zntl Investment And Other Income Expense
InvestmentAndOtherIncomeExpense
426000 USD
CY2021Q1 zntl Investment And Other Income Expense
InvestmentAndOtherIncomeExpense
99000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57453000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50248000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
196000 USD
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1751000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-59237000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-50444000 USD
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-160000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-543000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-59077000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-49901000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45244000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45244000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40359000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40359000 shares
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-59237000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-50444000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-984000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-60221000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-50430000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-160000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-543000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60061000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49887000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-59237000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-50444000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
344000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10147000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9691000 USD
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000 USD
CY2022Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
146000 USD
CY2021Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
289000 USD
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1751000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-169000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4154000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1357000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-574000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3307000 USD
CY2022Q1 zntl Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
1381000 USD
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1111000 USD
CY2021Q1 zntl Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
782000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50196000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37469000 USD
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
79254000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
54434000 USD
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
99500000 USD
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
68328000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
450000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
436000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19796000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13458000 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1258000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1258000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29142000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24011000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62584000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56271000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33442000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32260000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
226000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
67000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30572000 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28996000 USD
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
2870000 USD
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
3264000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33442000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32260000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
364482000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10147000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-984000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
645000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
612000 USD
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-160000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-59077000 USD
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
315666000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
333377000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9691000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
14000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-543000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-49901000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292638000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div>
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
35700000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
259905000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1108000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
258797000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
280298000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
137000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
280173000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
43 security
CY2022Q1 us-gaap Trading Securities Debt
TradingSecuritiesDebt
258800000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1100000 USD
CY2022Q1 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
245854000 USD
CY2021Q4 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
258948000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
12943000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
21225000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
258797000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
280173000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24668000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
43653000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
258797000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
280173000 USD
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
283465000 USD
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
323826000 USD
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
540000 USD
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
990000 USD
CY2022Q1 zntl Prepaid Software License And Maintenance
PrepaidSoftwareLicenseAndMaintenance
350000 USD
CY2021Q4 zntl Prepaid Software License And Maintenance
PrepaidSoftwareLicenseAndMaintenance
403000 USD
CY2022Q1 zntl Foreign Research And Development Credit Refund
ForeignResearchAndDevelopmentCreditRefund
1596000 USD
CY2021Q4 zntl Foreign Research And Development Credit Refund
ForeignResearchAndDevelopmentCreditRefund
1808000 USD
CY2022Q1 zntl Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
15926000 USD
CY2021Q4 zntl Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
11204000 USD
CY2022Q1 us-gaap Interest Receivable
InterestReceivable
266000 USD
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
258000 USD
CY2022Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2348000 USD
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2373000 USD
CY2022Q1 zntl Other Prepaid Expense
OtherPrepaidExpense
808000 USD
CY2021Q4 zntl Other Prepaid Expense
OtherPrepaidExpense
644000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
21834000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
17680000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
10164000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
7040000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11670000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10640000 USD
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9591000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8940000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
792000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8480000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8148000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
344000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79000 USD
CY2022Q1 zntl Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
21363000 USD
CY2021Q4 zntl Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
18531000 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5873000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9250000 USD
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
643000 USD
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
669000 USD
CY2022Q1 zntl Accrued General And Administrative Costs Current
AccruedGeneralAndAdministrativeCostsCurrent
477000 USD
CY2021Q4 zntl Accrued General And Administrative Costs Current
AccruedGeneralAndAdministrativeCostsCurrent
1480000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1269000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1453000 USD
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
697000 USD
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
971000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30322000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32354000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10147000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9691000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10147000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9691000 USD
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
33200 shares
CY2022Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
100000 shares
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2088000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6340000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6486000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6799000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7278000 USD
CY2022Q1 zntl Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
46229000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
75220000 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
28973000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
46247000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1269000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44978000 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40359000 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-59077000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-49901000 USD
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45244000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45244000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40359000 shares
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6092000 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5178000 shares

Files In Submission

Name View Source Status
0001725160-22-000093-index-headers.html Edgar Link pending
0001725160-22-000093-index.html Edgar Link pending
0001725160-22-000093.txt Edgar Link pending
0001725160-22-000093-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zentalis10-qq12022ex311.htm Edgar Link pending
zentalis10-qq12022ex312.htm Edgar Link pending
zentalis10-qq12022ex321.htm Edgar Link pending
zentalis10-qq12022ex322.htm Edgar Link pending
zntl-20220331.htm Edgar Link pending
zntl-20220331.xsd Edgar Link pending
zntl-20220331_cal.xml Edgar Link unprocessable
zntl-20220331_def.xml Edgar Link unprocessable
zntl-20220331_htm.xml Edgar Link completed
zntl-20220331_lab.xml Edgar Link unprocessable
zntl-20220331_pre.xml Edgar Link unprocessable